1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Leftfield Obesity Mechanism Hurts Shionogi

 
• By Elizabeth Cairns

When it comes to weight loss drug development, the sensible move is to follow the pack.    

Separate ways
• Source: Shutterstock

With GLP-1-based drugs ramping up staggering sales in obesity, and similar compounds in the clinic posting ever more impressive data, it is a brave company that chooses to pursue a non-incretin for the disorder. Shionogi & Co. Ltd. has learned that lesson the hard way, today disclosing disappointing results with its monoacylglycerol acyltransferase 2 inhibitor, S-309309.

Key Takeaways
  • Shionogi’s oral obesity drug S-309309 has disappointed in a Phase II trial.
  • It is a monoacylglycerol acyltransferase 2 inhibitor rather than a GLP-1 agonist-based drug

The group had been aiming for weight loss of 8%-10% after six months’ oral treatment with S-309309 in its Phase II obesity study. At its R&D day on 7 June, Shionogi admitted that the preliminary figure “did not exceed 5%”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.